Moreover, no reported substantial and corroborated clinical evidence exists that contradicts this ZIP1/zinc prostate will deliver zinc into ZIP1-deficient tumors; thereby effectively inhibiting tumor growth. Here, SLC39A1 is linked to neoplasm.